Globus Medical

Globus Medical has received CE marking for commercial distribution of its mobile imaging system Excelsius3D in the European Union and the United Kingdom. Excelsius3D combines 3D cone‑beam CT, 2D fluoroscopy and digital radiography and can be integrated into the robotic navigation system ExcelsiusGPS to enable intraoperative imaging and robot‑assisted navigation. The system was already cleared in the US in 2021 via 510(k); the stock rose slightly in after‑hours trading. » Plus sur de.investing.com

Globus Medical announced the acquisition of Higgs Boson Health, a Durham (North Carolina)-based digital-health startup spun out of Duke University. Higgs Boson brings software developers and AI scientists and will be integrated into Globus Medical’s division for digital health technologies. The technology will become part of the “Surgical Intelligence” pillar and be used across the entire patient journey; financial details were not disclosed. » Plus sur de.investing.com

Globus Medical reported Q2 revenue of $789.6 million and a record non‑GAAP EPS of $1.34; GAAP EPS of $1.10 matched analysts’ estimates. Adjusted EBITDA margin rose to 35.4% and the company generated strong operating cash flow of $412.1 million in the first half of the year. Globus reaffirmed full‑year revenue guidance of $3.18–3.22 billion and raised its non‑GAAP EPS outlook to $4.95–5.05; the stock reacted positively in after‑hours trading. Management cited margin expansion, market‑share gains in spine and trauma, and continued investments in the product pipeline and enabling technologies. » Plus sur de.investing.com